Ann: MDR Record FY24 Performance with Positive EBITDA and NPAT, page-29

Certainly not an organised group posting. Looks like a few who observed the spring tightening with very little high/low variation. Big volume in the push up, so not all would be flippers.

https://www.pymnts.com/healthcare/2...tform-is-creating-the-pharmacy-of-the-future/

US competitors in this space have US$B market caps - McKesson, Cardinal, Cerner.

I'm not sure I'm an advocate for take over just yet or even at all.

PME started small and is now $14B on $76M half year revenue (H1FY24).

But they are raking in the profits. Looking forward to MDR growing their profit margins.